

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Regenerative Medicine International Limited
中國再生醫學國際有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 8158)

**CHANGE OF
COMPANY SECRETARY AND AUTHORISED REPRESENTATIVE
AND
RE-DESIGNATION OF DIRECTOR**

The Board hereby announces that with effect from 11 January 2016:

- (i) Ms. Chan has resigned as the company secretary of the Company and the Authorised Representative;
- (ii) Mr. Cheng has been appointed as the company secretary of the Company; and
- (iii) Mr. Wong has been re-designated from a non-executive Director to an executive Director and has been appointed as the Authorised Representative.

The board (the “**Board**”) of directors (the “**Directors**”) of China Regenerative Medicine International Limited (the “**Company**”) hereby announces that with effect from 11 January 2016:

- (i) Ms. Chan Yim (“**Ms. Chan**”) has resigned as the company secretary and the authorised representative of the Company under the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited (the “**GEM Listing Rules**”) and for accepting service of process and notices on behalf of the Company in Hong Kong as required under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (collectively, the “**Authorised Representative**”);

- (ii) Mr. Cheng Chai Fu (“**Mr. Cheng**”) has been appointed as the company secretary of the Company; and
- (iii) Mr. Wong Sai Hung (“**Mr. Wong**”) has been re-designated from a non-executive Director to an executive Director and has been appointed as the Authorised Representative.

APPOINTMENT OF MR. CHENG AS COMPANY SECRETARY OF THE COMPANY

Following Ms. Chan’s resignation as the company secretary of the Company, Mr. Cheng has been appointed as the company secretary of the Company with effect from 11 January 2016.

Mr. Cheng graduated from Victoria University of Wellington, New Zealand with a bachelor degree of commerce and administration and obtained a Master of Business Administration from Murray State University, Kentucky of the United States of America. He is an associate member of The Hong Kong Institute of Chartered Secretaries with extensive experience in the areas of auditing, accounting and company secretarial work.

RE-DESIGNATION OF MR. WONG FROM NON-EXECUTIVE DIRECTOR TO EXECUTIVE DIRECTOR AND APPOINTMENT AS AUTHORISED REPRESENTATIVE

Following Ms. Chan’s resignation as the Authorised Representative, Mr. Wong has been re-designated from a non-executive Director to an executive Director and has been appointed as the Authorised Representative with effect from 11 January 2016.

Mr. Wong, aged 60, was a non-executive Director immediately prior to the re-designation and is the chairman of the Board. Mr. Wong joined the Group in June 2008 as a non-executive Director. Between August 2012 and April 2013, he had been re-designated as executive Director, and between July 2009 and August 2012 and from May 2013 to July 2014 as the vice-chairman of the Board. Mr. Wong graduated from Hong Kong Polytechnic University with a Higher Diploma in Business Studies (Marketing). Currently, he is an independent non-executive director of the Hong Kong Exchanges and Clearing Limited (the shares of which are listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), stock code: 388), Ping An Insurance (Group) Company of China, Ltd. (the shares of which are listed on the Main Board of the Stock Exchange, stock code: 2318) and JPMorgan Chinese Investment Trust plc (an investment trust listed on the London Stock Exchange); a non-executive director of Credit China Holdings Limited (the shares of which are listed on the Growth Enterprise Market (the “**GEM**”) of the Stock Exchange, stock code: 8207) and a director of One Asset Management Limited (a company incorporated in Thailand). Previously, Mr. Wong was an executive director of LW Asset Management Advisors Limited; a non-executive director of ARN Investment SICAV (an investment company listed on the Luxembourg Stock Exchange) and ARN Asian Enterprise Fund

Limited (formerly listed on the Irish Stock Exchange); the chief executive officer and an executive director of ICBC (Asia) Investment Management Company Limited; the chief executive director of BOCI Prudential Asset Management Limited and a regional managing director of Prudential Portfolio Managers Asia.

Mr. Wong holds 30,000,000 shares of the Company (the “**Shares**”) and 7,560,000 share options granted by the Company under the share option scheme adopted by the Company on 14 September 2011.

Mr. Wong has entered into a supplemental letter with the Company for continuation of his appointment for a term of two years commencing from 28 October 2014 to 27 October 2016, and he is subject to retirement by rotation and re-election at the annual general meeting in accordance with the articles of association of the Company. Mr. Wong is entitled to HK\$1,200,000 per annum as Director’s fee, with discretionary bonus, which is determined with reference to his duties and responsibilities being a non-executive Director. After his redesignation, the remuneration package to which Mr. Wong is entitled will remain unchanged.

Save as disclosed above:

- (i) Mr. Wong did not hold any directorships in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years and does not hold other major appointments and professional qualifications;
- (ii) Mr. Wong does not have any relationship with any directors, senior management, substantial shareholders or controlling shareholders of the Company or any of its subsidiaries;
- (iii) Mr. Wong does not have any interests or short positions in the Shares, underlying Shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and
- (iv) there is no other matter concerning Mr. Wong’s re-designation that needs to be brought to the attention of the shareholders of the Company nor any information that needs to be disclosed pursuant to the requirements of Rules 17.50(2)(h) to (v) of the GEM Listing Rules.

The Board would like to take this opportunity to express its gratitude to Ms. Chan for her valuable contributions to the Company during her tenure of service and express its warm welcome to Mr. Cheng on his appointment and to Mr. Wong for his new roles in the Company.

By order of the Board
China Regenerative Medicine International Limited
Dai Yumin
Executive Director

Hong Kong, 11 January 2016

As at the date of this announcement, the executive Directors are Mr. Dai Yumin, Ms. Wang Yurong and Mr. Wong Sai Hung; the non-executive Directors are Professor Deng Shaoping, Mr. Cao Fushun, Mr. Yang Zhengguo and Mr. Wang Jianjun; and the independent non-executive Directors are Mr. Lui Tin Nang, Mr. Pang Chung Fai Benny, Mr. Chan Bing Woon, SBS, JP and Mr. Wang Hui.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcement” page of the GEM website at www.hkgem.com for at least seven days from the date of the publication and will be published on the website of the Company at www.crmi.hk.